Related Experiment Video

Updated: Aug 6, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Emerging approaches in molecular profiling affecting oncology drug discovery

S H Friend1

  • 1Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

Cold Spring Harbor Symposia on Quantitative Biology
|July 28, 2006
PubMed

Insights

We are at a tipping point in oncology and drug discovery, leveraging model organisms and biomarkers for more efficient patient care. Future oncology research will integrate target identification and patient response identification processes.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomarker Research

Background:

  • Model organisms have historically contributed to advancements in drug discovery.
  • Biomarkers are increasingly integrated into clinical practice for personalized medicine.
  • Understanding patient response to drugs is crucial for effective oncology treatment.

Purpose of the Study:

  • To assess if current advancements signify a tipping point in oncology and drug discovery.
  • To highlight the role of model organisms in accelerating drug discovery.
  • To discuss the integration of biomarkers and future trends in identifying drug responders.

Main Methods:

  • Review of historical contributions of model organisms in drug discovery.
  • Analysis of current trends in biomarker integration for patient care.
  • Prospective analysis of target identification and responder identification processes.

Main Results:

  • Model organisms have paved the way for more efficient oncology drug discovery.
  • Biomarker integration in patient care is a rapidly emerging field.
  • Target identification and identification of drug responders are converging processes.

Conclusions:

  • The field of oncology and drug discovery is at a critical juncture.
  • Continued integration of biomarkers and streamlined identification processes will enhance oncology treatments.
  • Collaboration is essential to connect the diverse components of modern drug discovery.

More Related Videos

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...